original articlesurogenital tumorsEfficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial
urogenital tumors
Under an Elsevier user license
open archive
Key words
renal cell carcinoma
angiogenesis
hypoxia-inducible factor
nanoparticle–drug conjugate
recommended phase II dose
CRLX101
Cited by (0)
Copyright © 2016 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.